Status:
COMPLETED
A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the effects of both single and multiple dose drug levels of MYK-224 in healthy adult Japanese participants.
Eligibility Criteria
Inclusion
- Healthy as determined by medical history, physical examination, vital signs,12-lead electrocardiogram and routine laboratory assessments
- Must have documented left Ventricular Ejection Fraction (LVEF) ≥60% (2D biplane Simpson's Method) at screening as determined by the echocardiographic core laboratory.
Exclusion
- Any acute or chronic medical illness
- History of heart disease
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
July 12 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 9 2022
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT05405543
Start Date
July 12 2022
End Date
December 9 2022
Last Update
January 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Anaheim, California, United States, 92801